Precision Cell Systems Acquires BennuBio

AnaBios Acquires Cell Systems

April 4, 2023

Biotechnology

AnaBios Corporation has acquired Cell Systems, a Kirkland, Washington supplier of human primary cells and cell culture media, to expand its human tissue and cell portfolio and accelerate translational drug discovery. Financing for the transaction was provided by AnaBios' existing investors, including Ampersand Capital Partners; financial terms were not disclosed.

Bio-Techne Acquires Namocell

June 22, 2022

Medical Devices

Bio-Techne Corporation has agreed to acquire Namocell, Inc., a Mountain View–based provider of single-cell sorting and dispensing platforms, with the deal expected to close in Bio-Techne's fiscal 2023 Q1. Namocell's Pala and Hana systems (installed base approaching 200 placements, ~60 sold in 2021) will complement Bio-Techne's Cell and Gene Therapy franchise and create commercial synergies across its analytical instruments sales force.

CellBio Scientific Acquires BioChain

May 1, 2025

Biotechnology

CellBio Scientific, a provider of life science tools and research services, has acquired BioChain, a biospecimen collection, preparation, and analysis company based in Newark, California. The acquisition expands CellBio Scientific's capabilities in spatial genomics and biospecimen workflows, consolidating BioChain with System Biosciences and Acepix Biosciences to create a broader translational research platform.

PerkinElmer Acquires Nexcelom Bioscience for $260M

May 13, 2021

Medical Devices

PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Cell Microsystems Acquires Fluxion Biosciences

August 23, 2023

Medical Devices

Durham-based Cell Microsystems has acquired Fluxion Biosciences, adding Fluxion's IonFlux, BioFlux and IsoFlux instruments and services to its CellRaft-based product portfolio. The deal is supported by a concurrent Series B financing led by Telegraph Hill Partners to provide growth capital and accelerate product and service integration for cellular analysis and electrophysiology workflows.